Literature DB >> 7666509

Human cytomegalovirus neutralizing antibody-resistant phenotype is associated with reduced expression of glycoprotein H.

L Li1, K L Coelingh, W J Britt.   

Abstract

We have characterized a neutralizing antibody-resistant mutant human cytomegalovirus (HCMV) obtained from a patient treated with a human monoclonal antiglycoprotein H (gH; unique long region 75) antibody. This virus exhibited resistance to several different neutralizing anti-gH murine monoclonal antibodies (MAbs), as well as to a polyvalent anti-gH serum. The resistant phenotype was unstable and could be maintained only by passage of plaque-purified virus under neutralizing MAb selection. In the absence of a MAb, the resistant phenotype reverted to a neutralizing antibody-sensitive phenotype within one passage. The predicted amino acid sequences of gH from the MAb-resistant and -susceptible parent viruses were identical. Biochemical analysis of the MAb-resistant and -susceptible parent viruses revealed a marked decrease of gH expression in the envelope of the MAb-resistant virus. Furthermore, propagation of the virus in various MAb concentrations resulted in the production of extracellular virions with various levels of resistance to the neutralizing activity of the MAb. These results suggest a mechanism for the generation of neutralizing antibody-resistant viruses which could evade host-derived antiviral antibody responses. In addition, our findings indicate that the stoichiometry of gH in the envelope of infectious HCMV virions is not rigidly fixed and therefore offer a simple explanation for production of phenotypic variants of HCMV through an assembly process in which the content of gH in the envelope of progeny virions varies randomly.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7666509      PMCID: PMC189501     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus.

Authors:  W J Britt; D Auger
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

2.  Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation.

Authors:  D J Winston; W G Ho; C H Lin; K Bartoni; M D Budinger; R P Gale; R E Champlin
Journal:  Ann Intern Med       Date:  1987-01       Impact factor: 25.391

3.  Antibody-induced modulation of Friend virus cell surface antigens decreases virus production by persistent erythroleukemia cells: influence of the Rfv-3 gene.

Authors:  B Chesebro; K Wehrly; D Doig; J Nishio
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

4.  Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome.

Authors:  S Stagno; R F Pass; G Cloud; W J Britt; R E Henderson; P D Walton; D A Veren; F Page; C A Alford
Journal:  JAMA       Date:  1986-10-10       Impact factor: 56.272

Review 5.  Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  Rev Infect Dis       Date:  1982 Nov-Dec

6.  Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.

Authors:  W J Britt
Journal:  Virology       Date:  1984-06       Impact factor: 3.616

Review 7.  Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.

Authors:  M A Jacobson; J Mills
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

8.  Identification and expression of a human cytomegalovirus glycoprotein with homology to the Epstein-Barr virus BXLF2 product, varicella-zoster virus gpIII, and herpes simplex virus type 1 glycoprotein H.

Authors:  M P Cranage; G L Smith; S E Bell; H Hart; C Brown; A T Bankier; P Tomlinson; B G Barrell; T C Minson
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

9.  The immunology of cytomegalovirus infection.

Authors:  J G Sissons
Journal:  J R Coll Physicians Lond       Date:  1986-01

10.  Identification of a unique erythroleukemia-associated retroviral gp70 expressed during early stages of normal erythroid differentiation.

Authors:  W J Britt; B Chesebro; J L Portis
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

View more
  21 in total

1.  Seminal plasma and semen amyloids enhance cytomegalovirus infection in cell culture.

Authors:  Qiyi Tang; Nadia R Roan; Yasuhiro Yamamura
Journal:  J Virol       Date:  2013-09-11       Impact factor: 5.103

2.  Cytomegalovirus Virions Shed in Urine Have a Reversible Block to Epithelial Cell Entry and Are Highly Resistant to Antibody Neutralization.

Authors:  Xiaohong Cui; Stuart P Adler; Mark R Schleiss; Ravit Arav-Boger; Gail J Demmler Harrison; Michael A McVoy
Journal:  Clin Vaccine Immunol       Date:  2017-06-05

3.  Identification and characterization of the guinea-pig cytomegalovirus glycoprotein H gene.

Authors:  R C Brady; M R Schleiss
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 4.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

5.  Comparative analysis of gO isoforms reveals that strains of human cytomegalovirus differ in the ratio of gH/gL/gO and gH/gL/UL128-131 in the virion envelope.

Authors:  Momei Zhou; Qin Yu; Anya Wechsler; Brent J Ryckman
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

Review 6.  Respiratory syncytial virus genetic and antigenic diversity.

Authors:  W M Sullender
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

Review 7.  Synthetic DNA approach to cytomegalovirus vaccine/immune therapy.

Authors:  Stephan J Wu; Daniel O Villarreal; Devon J Shedlock; David B Weiner
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  Combination of immunoglobulins and natural killer cells in the context of CMV and EBV infection.

Authors:  K Frenzel; J Lehmann; D H Krüger; L Martin-Parras; L Uharek; J Hofmann
Journal:  Med Microbiol Immunol       Date:  2013-12-15       Impact factor: 3.402

9.  Antiviral function and efficacy of polyvalent immunoglobulin products against CMV isolates in different human cell lines.

Authors:  K Frenzel; S Ganepola; D Michel; E Thiel; D H Krüger; L Uharek; J Hofmann
Journal:  Med Microbiol Immunol       Date:  2012-08       Impact factor: 3.402

10.  Glycoprotein H-related complexes of human cytomegalovirus: identification of a third protein in the gCIII complex.

Authors:  L Li; J A Nelson; W J Britt
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.